ChromaDexCDXC
About: ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.
Employees: 106
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
119% more call options, than puts
Call options by funds: $379K | Put options by funds: $173K
65% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 17
25% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 16
16% more funds holding
Funds holding: 67 [Q1] → 78 (+11) [Q2]
4.39% more ownership
Funds ownership: 17.49% [Q1] → 21.88% (+4.39%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
2% less capital invested
Capital invested by funds: $45.8M [Q1] → $45.1M (-$715K) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 111 / 288 met price target | 69%upside $6 | Buy Reiterated | 9 Aug 2024 |
HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 111 / 288 met price target | 69%upside $6 | Buy Reiterated | 15 Jul 2024 |
Financial journalist opinion
Based on 3 articles about CDXC published over the past 30 days